Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical Group's quarterly market cap
increased
from Dec. 2024 (HK$6,906 Mil) to Jun. 2025 (HK$9,626 Mil) and
increased
from Jun. 2025 (HK$9,626 Mil) to Dec. 2025 (HK$13,089 Mil).
Consun Pharmaceutical Group's annual market cap
increased
from Dec. 2023 (HK$3,780 Mil) to Dec. 2024 (HK$6,906 Mil) and
increased
from Dec. 2024 (HK$6,906 Mil) to Dec. 2025 (HK$13,089 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Consun Pharmaceutical Group's Enterprise Value for Today is HK$8,559 Mil.
Consun Pharmaceutical Group (HKSE:01681) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Consun Pharmaceutical Group Market Cap Related Terms
Consun Pharmaceutical Group Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Market Cap falls into.
Consun Pharmaceutical Group Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (HKSE:01681) has a Market Cap of HK$11,570 Mil as of Aug. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Consun Pharmaceutical Group and its competitors. According to the industry distribution chart, Consun Pharmaceutical Group ranks #209 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 20.5%.
Is Consun Pharmaceutical Group's Market Cap too high?
Consun Pharmaceutical Group's current Market Cap is HK$11,570 Mil. Based on the distribution chart, Consun Pharmaceutical Group ranks #209 out of 1022 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #209 out of 1022 companies for Market Cap. This places Consun Pharmaceutical Group in the top 21% of its industry — outperforming the majority of peers. The industry median Market Cap is 229.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 229.72, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Market Cap is 229.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Market Cap is HK$11,570 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (HKSE:01681) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$8.57, compared to a current price of HK$13.79 — trading 60.9% above its estimated fair value. The current Market Cap is HK$11,570 Mil. Consun Pharmaceutical Group's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Consun Pharmaceutical Group (HKSE:01681), the current Market Cap is HK$11,570 Mil as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (HKSE:01681) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of HK$13.79 is trading 60.9% above its estimated GF Value™ of HK$8.57.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for HKSE:01681:
Market Cap: HK$11,570 Mil
GF Value™: HK$8.57 vs. price of HK$13.79 (60.9% above fair value)
No single metric tells the full story. See the HKSE:01681 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
87GF Score
Get the complete analysis for HKSE:01681
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01681 has been successfully added to your 
